Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Rating) Director Robert W. Duggan acquired 10,022,937 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was purchased at an average price of $6.51 per share, for a total transaction of $65,249,319.87. Following the acquisition, the director now directly owns 30,414,661 shares of the company’s stock, valued at approximately $197,999,443.11. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Pulse Biosciences Stock Down 8.3 %
Shares of PLSE stock opened at $7.61 on Friday. The stock has a market cap of $286.06 million, a P/E ratio of -4.32 and a beta of 1.13. Pulse Biosciences, Inc. has a one year low of $1.18 and a one year high of $9.69. The stock has a fifty day moving average price of $4.74 and a 200 day moving average price of $3.36. The company has a debt-to-equity ratio of 10.50, a current ratio of 10.39 and a quick ratio of 10.39.
Pulse Biosciences (NASDAQ:PLSE – Get Rating) last released its quarterly earnings data on Thursday, March 30th. The company reported ($0.24) earnings per share (EPS) for the quarter. The business had revenue of ($0.01) million during the quarter.
Analyst Upgrades and Downgrades
Institutional Trading of Pulse Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in shares of Pulse Biosciences during the 2nd quarter valued at about $184,000. Griffin Asset Management Inc. boosted its stake in Pulse Biosciences by 104.9% in the 4th quarter. Griffin Asset Management Inc. now owns 175,893 shares of the company’s stock valued at $487,000 after purchasing an additional 90,059 shares during the period. Renaissance Technologies LLC bought a new stake in Pulse Biosciences in the 1st quarter valued at $378,000. Spotlight Asset Group Inc. bought a new stake in shares of Pulse Biosciences during the 3rd quarter valued at $147,000. Finally, Occudo Quantitative Strategies LP lifted its position in shares of Pulse Biosciences by 217.3% during the 2nd quarter. Occudo Quantitative Strategies LP now owns 58,383 shares of the company’s stock worth $54,000 after buying an additional 39,981 shares during the last quarter. 6.56% of the stock is currently owned by institutional investors and hedge funds.
About Pulse Biosciences
Pulse Biosciences, Inc operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling.
- Get a free copy of the StockNews.com research report on Pulse Biosciences (PLSE)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.